Conference report--extracellular matrix and cancer: revisiting metalloproteinases highlights from the annual meeting of the American Society for Cell Biology; December 13-17, 2003; San Francisco, California.

Inflammation and cancer. Nature (2002) 53.78

New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71

Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57

Stromal effects on mammary gland development and breast cancer. Science (2002) 5.22

The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation (2002) 4.64

Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell (2003) 4.56

Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol (2000) 3.53

The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol (2001) 3.22

Extracellular matrix and integrin signalling: the shape of things to come. Biochem J (1999) 2.28

Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24

Matrix metalloproteinases in tumor-host cell communication. Differentiation (2002) 2.16

HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells (2002) 1.94

Beyond homeosis--HOX function in morphogenesis and organogenesis. Differentiation (2003) 1.72

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol (2002) 1.72

Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem (2002) 1.67

Homeobox genes in normal and malignant cells. J Cell Physiol (2001) 1.54

Sustained expression of homeobox D10 inhibits angiogenesis. Am J Pathol (2002) 1.44

Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38

New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol (2003) 1.31

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol (1998) 1.25

Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res (1998) 1.22

HoxD3 accelerates wound healing in diabetic mice. Am J Pathol (2003) 1.09

Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol Biotechnol (2003) 1.01

Basement membrane and interstitial proteoglycans produced by MDCK cells correspond to those expressed in the kidney cortex. Matrix Biol (2001) 0.93

The study of HOX gene function in hematopoietic, breast and lung carcinogenesis. Anticancer Res (2003) 0.88

Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma. J Soc Gynecol Investig (1998) 0.86

Reconstruction of peritoneal-like structure in three-dimensional collagen gel matrix culture. Exp Cell Res (1997) 0.77

Neuroethics: how to leave the cave without going astray: highlights from the Annual Meeting of the American Society of Neuroscience; November 8-12, 2003; New Orleans, Louisiana. MedGenMed (2003) 0.92

Genes and autoimmune diseases - a complex inheritance. MedGenMed (2004) 0.83

Anti-angiogenesis: the challenges ahead. MedGenMed (2003) 0.80

MedGenMed Hematology/Oncology conference report--plenary session: from genes to cells to metastasis. Highlights from the 2003 annual meeting of the American Association for Cancer Research. MedGenMed (2003) 0.78

Antiangiogenesis cocktails - stirred or shaken? MedGenMed (2004) 0.76

Progress in human genetics. MedGenMed (2004) 0.75

Amyloid, tau, and cell death in Alzheimer's disease. MedGenMed (2004) 0.75

Conference report--genomics: the promise of SNPs and bats highlights of the ABRF 2004--integrating technologies in proteomics and genomics; February 28-March 2, 2004; Portland, Oregon. MedGenMed (2004) 0.75

Conference report--cancer research 2004--top of the class March 27-March 31, 2004; Orlando, Florida. MedGenMed (2004) 0.75

Conference report--early cancer diagnosis: beating the odds. MedGenMed (2004) 0.75

Conference report--dendritic cells: myths and reality highlights from the annual meeting of the American Society for Cell Biology; December 13-17, 2003; San Francisco, California. MedGenMed (2004) 0.75

Conference report--stem cells and neurologic repair: highlights from the annual meeting of the American Society of Neuroscience; November 8-12, 2003; New Orleans, Louisiana. MedGenMed (2004) 0.75

Conference report--gene therapy and lung cancer--no time to wait. MedGenMed (2004) 0.75

Conference report--structural genomics: parsing the architecture of proteins highlights of the ABRF 2004--integrating technologies in proteomics and genomics, February 28-March 2, 2004; Portland, Oregon. MedGenMed (2004) 0.75

ApoE and Alzheimer's disease--10 years later. MedGenMed (2004) 0.75

Conference report - transfusions and TRALI: what are the risks today? Highlights from the 71st Annual Meeting of the American Society for Clinical Laboratory Science; July 22-26, 2003; Philadelphia, Pennsylvania. MedGenMed (2003) 0.75

Functional genomics: improving cancer prognosis and drug development. MedGenMed (2003) 0.75

Conference report - magic markers for the diagnosis of thyroid carcinomas? Highlights from the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana. MedGenMed (2003) 0.75

Spongiform encephalopathies: a tale of cannibals, cattle, and prions. MedGenMed (2003) 0.75

Functional genomics: a holistic approach. MedGenMed (2003) 0.75

Conference report - apoptosis - a graceful death: highlights from the 2003 Annual Meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC. MedGenMed (2003) 0.75

MedGenMed Hematology/Oncology conference report--translational research: any danger lurking in its wake? Highlights from the 2003 annual meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC. MedGenMed (2003) 0.75

Severe immunodeficiencies: bone marrow transplantation or gene therapy? MedGenMed (2003) 0.75

Conference report - clinical pathology: the top 5 studies in the journal: highlights from the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana. MedGenMed (2003) 0.75

Stem cells: dreams or reality? MedGenMed (2003) 0.75

Cancer and the immune response: improving the odds. MedGenMed (2003) 0.75

Stem cells: a plenary policy forum. MedGenMed (2003) 0.75

Clinical proteomics: new promises for early cancer detection. MedGenMed (2003) 0.75

Targeting cancer cells -- more pathways, more inhibitors, more trails. Highlights of 9th annual Drug Discovery Technology World Congress; August 8-13, 2004; Boston, Massachusetts. MedGenMed (2004) 0.75

MedGenMed hematology/oncology conference report--dangerous liaisons: infections and cancer--time for a break-up? Highlights from the 2003 annual meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC. MedGenMed (2003) 0.75

Conference report - breast cancer markers: what next? Highlights from the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana. MedGenMed (2003) 0.75

Biodefense research: new tricks to fight old enemies. MedGenMed (2003) 0.75

Breast cancer: prevention, prediction, and treatment. MedGenMed (2003) 0.75